Explore Our Diverse Range Of Offerings
From detailed reports to experts services offered in 15+ Industry Domains
Report
Press Release
Blogs
Industry Statistics
Add 2 More Reports For 20% off

Report Overview

Mycobacteria species other than Mycobacterium tuberculosis and M. leprae are responsible for nontuberculous mycobacterial (NTM) infections. These environmental bacteria frequently infects individuals with compromised immune systems or long-term lung conditions, infecting the lungs, lymph nodes, skin, and soft tissues. Skin ulcers, exhaustion, weight loss, and a persistent cough are some of the symptoms. Imaging and cultures are necessary for diagnosis. To guarantee recovery and avoid resistance, treatment entails lengthy multi-drug antibiotic regimens that can continue anywhere from months to years, occasionally in conjunction with surgery. The nontuberculous mycobacterial infections pipeline analysis by Expert Market Research focuses on various treatment options for this disease.

Q1 2026 Market Updates

Overview: When the Iran-US-Israel conflict erupted in Q1 2026, its effects rippled through the Nontuberculous Mycobacterial Infections Pipeline Insight space in ways that buyers and suppliers had to navigate quickly. Demand and supply chain dynamics for the global nontuberculous mycobacterial infections pipeline insight market. Energy infrastructure investment acceleration, driven by the need to substitute for QatarEnergy supply disruption following QatarEnergy force majeure declared following Ras Laffan drone strikes on March 2, 2026 and to maximize production at Brent crude at USD 126/barrel (Wikipedia) , stepped-up procurement of oil and gas pipeline, process piping, and hydraulic system components. LNG terminal construction and expansion programs generated lifted demand for cryogenic, high-pressure, and specialty piping systems. Construction activity supported by defense facility programs and infrastructure investment maintained water, drain, and plumbing system procurement across the building sector.

United States: For US-based companies in this space, US nontuberculous mycobacterial infections pipeline insight market demand during the first quarter of 2026 was driven by energy infrastructure investment, with LNG terminal expansion and oil and gas production maximization generating stepped-up procurement of line pipe, process piping, and flow control components for new and upgraded energy infrastructure. US residential and commercial construction activity, supported by infrastructure investment programs and defense facility development, maintained plumbing, drain, and water supply piping demand. US water and wastewater utility infrastructure investment, elevated by Q1 2026 resilience priorities, generated demand for water main pipe replacement and treatment facility piping upgrades. Polymer and PVC pipe manufacturers, Nexeo, Charlotte Pipe, and Georg Fischer, navigated elevated resin costs from petrochemical feedstock price increases linked to Brent crude at USD 126/barrel (Wikipedia).

Iran & Israel: Gulf state oil and gas pipeline and process piping investment, with Saudi Aramco, ADNOC, and QatarEnergy maximizing production and expanding facility capacity during Q1 2026, generated stepped-up procurement of high-specification line pipe, process piping, and flow control components across major producing regions. Israel's water infrastructure, including the National Water Carrier pipeline network and desalination plant piping systems, maintained priority investment in pipe replacement, leak detection, and resilience upgrades throughout Q1 2026 as water security is a national strategic priority. Iranian oil and gas pipeline and process piping infrastructure, subject to Q1 2026 strikes on energy and industrial facilities, sustained damage across conflict-affected provinces, compounding existing deterioration from sanctions-limited maintenance and pipe replacement access.

Key Takeaways

Government & Policy Watch

  • LNG infrastructure demand: US and global LNG terminal expansion, accelerated by QatarEnergy supply disruption, is driving stepped-up procurement of cryogenic, high-pressure, and process piping systems for terminal construction and expansion.
  • Oil and gas pipeline investment: US and GCC oil and gas pipeline and facility expansion, driven by high commodity prices, is generating procurement demand for line pipe, process piping, and flow control components across energy infrastructure.
  • Water infrastructure resilience: US and allied-nation water utility infrastructure investment, elevated by Q1 2026 resilience priorities, is driving pipe replacement and treatment facility piping upgrade programs.

Market & Industry Impact

  • Market growth: The nontuberculous mycobacterial infections pipeline insight market is growing on energy infrastructure expansion, water utility investment, residential and commercial construction, and industrial facility development, with Q1 2026 energy investment providing near-term demand acceleration.
  • Polymer pipe growth: PVC, PE, and CPVC piping systems, offering corrosion resistance, lighter weight, and lower installation cost versus metal alternatives, are one of the faster-growing pipe categories across water, drainage, and process applications.
  • Smart piping: Intelligent pigging, sensor-embedded pipe systems, and IoT-connected leak detection are growing in adoption for oil and gas and water utility pipeline management, driven by asset integrity and regulatory compliance requirements.

Procurement & Supply Chain Alert

  • Resin cost exposure: PVC and PE pipe manufacturing depends on petroleum-derived polymer resins, with Q1 2026 energy price increases elevating feedstock costs and compressing pipe manufacturer margins.
  • Steel pipe supply: Steel line pipe supply is affected by global steel market conditions and Q1 2026 supply chain disruption, with mill lead times extending as energy infrastructure investment creates lifted demand across steel pipe categories.
  • Installation constraints: Pipeline construction and piping installation require certified welders, pipefitters, and specialized heavy equipment, workforce and equipment availability constraints that limit project execution speed.
  • Major companies involved in the nontuberculous mycobacterial infections pipeline analysis include Insmed Incorporated, Janssen Pharmaceutical K.K., and AN2 Therapeutics, Inc., among others.

  • Leading drugs currently in the pipeline include ALIS, Bedaquiline, and others.

  • Increased investment in research and development, along with regulatory support, is accelerating clinical trials and new treatment approvals.

Report Coverage

The Nontuberculous Mycobacterial Infections Pipeline Analysis Report by Expert Market Research gives comprehensive insights into nontuberculous mycobacterial infections therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for nontuberculous mycobacterial infections. The nontuberculous mycobacterial infections report assessment includes the analysis of over 15 pipeline drugs and 10+ companies. The nontuberculous mycobacterial infections pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with nontuberculous mycobacterial infections treatment guidelines to ensure optimal care practices.

The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to nontuberculous mycobacterial infections.

Nontuberculous Mycobacterial Infections Pipeline Analysis By Drug Class

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Nontuberculous Mycobacterial Infections Pipeline Outlook

Environmental exposure to species like Mycobacterium avium complex, which defy host defenses by limiting phagosome development and resisting oxidative stress, can result in nontuberculous mycobacterial (NTM) infections. Bacterial clearance is hampered by host vulnerability, which includes weakened immunity (such as abnormalities in the IFN-γ/IL-12 pathways) or structural lung injury (such as bronchiectasis). Granuloma growth, airway damage, and symptoms like cough and exhaustion are caused by chronic inflammation brought on by a persistent infection. Prolonged use of antibiotics that target intracellular bacteria is necessary for treatment.

Nontuberculous mycobacterial (NTM) infections are usually treated with a long-term combination antibiotic regimen that is specific to the NTM species. A macrolide (clarithromycin or azithromycin), ethambutol, and rifampin or rifabutin are frequently included in regimens for Mycobacterium avium complex (MAC). These medications are given daily or three times a week for a year following sputum culture conversion. In severe situations, injectable streptomycin or amikacin may be added first. The average course of treatment lasts 12 to 24 months. For complex, resistant, or localized pulmonary illness, surgery may be an option. Throughout treatment, it is crucial to keep an eye out for drug toxicity.

Nontuberculous Mycobacterial Infections Epidemiology

Nontuberculous mycobacterial (NTM) infections are becoming more common, particularly in individuals with non-cystic fibrosis bronchiectasis, where the frequency is approximately 10%. In the United States, the overall rate of NTM pulmonary disease increased from about 2.4 cases per 100,000 in the 1980s to over 15 cases per 100,000 by 2013. Regional rates are influenced by geography and environmental factors, and prevalence is higher in women and older people. Globally, including in Asia, Europe, and North America, rising patterns are being recorded.

Nontuberculous Mycobacterial Infections – Drug Pipeline Therapeutic Assessment

This section of the report covers the analysis of nontuberculous mycobacterial infections drug candidates based on several segmentations, including:

By Phase

  • Late-Stage Products (Phase 3 and Phase 4)
  • Mid-Stage Products (Phase 2)
  • Early-Stage Products (Phase I)
  • Preclinical and Discovery Stage Products

By Drug Class

  • Recombinant fusion proteins
  • Small molecule
  • Monoclonal antibody
  • Peptide
  • Polymer
  • Gene therapy

By Route of Administration

  • Oral
  • Parenteral
  • Others

Nontuberculous Mycobacterial Infections – Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, in the nontuberculous mycobacterial infections pipeline, maximum candidates are concentrated in Phase III with 60% of the projects followed by Phase II. Thus, demonstrating a broad spectrum of development stages and diverse progress toward potential treatments.

Nontuberculous Mycobacterial Infections – Pipeline Assessment Segmentation, By Drug Classes

The drug molecule categories covered under the nontuberculous mycobacterial infections pipeline analysis include recombinant fusion proteins, small molecules, monoclonal antibodies, peptides, polymers and gene therapies. The nontuberculous mycobacterial infections report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for nontuberculous mycobacterial infections.

Nontuberculous Mycobacterial Infections Clinical Trials – Key Players

The EMR report for the nontuberculous mycobacterial infections pipeline analysis covers the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in nontuberculous mycobacterial infections clinical trials:

  • Insmed Incorporated
  • Janssen Pharmaceutical K.K.
  • AN2 Therapeutics, Inc.

Nontuberculous Mycobacterial Infections – Emerging Drugs Profile

This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for nontuberculous mycobacterial infections. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of nontuberculous mycobacterial infections drug candidates.

Drug: ALIS

Insmed Incorporated created Amikacin Liposome Inhalation Suspension (ALIS), an inhaled liposomal formulation of amikacin intended to treat lung illness caused by the refractory Mycobacterium avium complex (MAC). High quantities of amikacin are delivered straight to the lungs by ALIS, which is administered via the LamiraTM nebulizer. This improves absorption into macrophages and allows it to penetrate biofilms. Adults with treatment-refractory MAC lung infections are being evaluated for safety and effectiveness as a supplement to guideline-based therapy in the current Phase III trial.

Drug: Bedaquiline

​The diarylquinoline antimycobacterial drug bedaquiline, created by Janssen Pharmaceutical K.K., prevents mycobacteria from producing energy by blocking their ATP synthase. Its effectiveness against nontuberculous mycobacterial (NTM) infections is being studied, despite the fact that it is licensed for multidrug-resistant tuberculosis (MDR-TB). In order to determine bedaquiline's safety and efficacy in treating treatment-refractory Mycobacterium avium complex lung illness, the ongoing Phase III trial assesses the medication in combination with clarithromycin and ethambutol.

*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*

Key Questions Answered in the Nontuberculous Mycobacterial InfectionsPipeline Analysis Report

  • Which companies/institutions are leading the nontuberculous mycobacterial infections drug development?
  • What is the efficacy and safety profile of nontuberculous mycobacterial infections pipeline drugs?
  • Which company is leading the nontuberculous mycobacterial infections pipeline development activities?
  • What is the current nontuberculous mycobacterial infections commercial assessment?
  • What are the opportunities and challenges present in the nontuberculous mycobacterial infections pipeline landscape?
  • Which company is conducting major trials for nontuberculous mycobacterial infections drugs?
  • Which companies/institutions are involved in nontuberculous mycobacterial infections collaborations aimed at providing enhanced therapeutic alternatives for patients?
  • What are the geographies covered for clinical trials in nontuberculous mycobacterial infections?

Related Reports

Hepatitis B Virus (HBV) Infection Drug Pipeline Analysis Report

Global Clinical Trials Market

*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*

Looking for specific insights?

Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!

Report Summary

Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.

Key Highlights of the Report

Please note that the figures mentioned in the description serve as estimates and may vary from the actual figures presented in the final report.

Scope of the Report

Details

Drug Pipeline by Clinical Trial Phase

  • Late-Stage Products (Phase III and Phase IV)
  • Mid-Stage Products (Phase II)
  • Early-Stage Products (Phase I)
  • Preclinical and Discovery Stage Products

Route of Administration

  • Oral
  • Parenteral
  • Others

Drug Classes

  • Recombinant fusion proteins
  • Small molecule
  • Monoclonal antibody
  • Peptide
  • Polymer
  • Gene therapy

Leading Sponsors Covered

  • Insmed Incorporated
  • Janssen Pharmaceutical K.K.
  • AN2 Therapeutics, Inc.

Geographies Covered

  • North America
  • Europe
  • Asia Pacific
  • Others

Mini Report

10 % Off

USD

1,999

1,799

Single User License

10 % Off

USD

3,099

2,789

Five User License

15 % Off

USD

4,599

3,909

Corporate License

15 % Off

USD

5,999

5,099

Mini Report

One User

USD 1,999

USD 1,799

tax inclusive*

  • Selected Segments
  • Printing Restrictions
  • Excel Spreadsheet Delivered via Email
  • Full Report
  • Periodic Updates
  • Post Sales Analysts Support
  • Unlimited Prints

Single User License

One User

USD 3,099

USD 2,789

tax inclusive*

  • All Segments
  • Printing Restrictions
  • PDF Delivered via Email
  • Custom Report Layout
  • Post Sales Analysts Support
  • Periodic Updates
  • Unlimited Prints

Five User License

Five User

USD 4,599

USD 3,909

tax inclusive*

  • All Segments
  • Five Prints Available
  • PDF Delivered via Email
  • Limited Free Customization
  • Post Sales Analyst Support
  • Custom Report Layout
  • Periodic Updates
  • Unlimited Prints

Corporate License

Unlimited Users

USD 5,999

USD 5,099

tax inclusive*

  • All Segments
  • Unlimited Prints Available
  • PDF & Excel Delivery via Email
  • Limited Free Customization
  • Post Sales Analysts Support
  • Discount On Next Update
  • Custom Report Layout

*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*

Bundle Type

Flash Bundle

20% OFF Number of Reports: 3

Small Business Bundle

25% OFF Number of Reports: 5

Growth Bundle

30% OFF Number of Reports: 8

Enterprise Bundle

35% OFF Number of Reports: 10
Overview
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complimentary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complimentary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 80 Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complimentary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 100 Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complimentary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards

*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*

Flash Bundle

Number of Reports: 3

20%

tax inclusive*

  • 3 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • Complimentary Excel Data Set
  • PPT Version of the Report
  • Power BI Dashboards
  • License Upgrade
  • Free Analyst Hours

Small Business Bundle

Number of Reports: 5

25%

tax inclusive*

  • 5 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • Complimentary Excel Data Set
  • PPT Version of the Report
  • Power BI Dashboards
  • License Upgrade

Growth Bundle

Number of Reports: 8

30%

tax inclusive*

  • 8 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • License Upgrade
  • Free Analyst Hours - 80 Hours
  • Power BI Dashboards

Enterprise Bundle

Number of Reports: 10

35%

tax inclusive*

  • 10 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • License Upgrade
  • Power BI Dashboards
  • Free Analyst Hours - 100 Hours

How To Order

This is a collaborative report by Vishakha Agrawal reflecting perspectives and research-driven insights from Expert Market Research.

Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.

License Type

Select License Type

Choose the right license for your needs and access rights.

shopping cart

Click on ‘Buy Now’

Add the report to your cart with one click and proceed to register.

Bookmark Icon

Select Mode of Payment

Choose a payment option for a secure checkout. You will be redirected accordingly.

Strategic Solutions for Informed Decision-Making

Connect For More Information

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.

Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.

We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.

We’re here to help answer any questions about our products and services.

Contact us